Integrated analysis of efficacy and safety of palonosetron (PALO) 0.75 mg IV for preventing chemotherapy-induced nausea and vomiting (CINV) in anthracycline and cyclophosphamide (AC/EC) combination chemotherapy in Japan: PALO Japanese breast cancer cooperative study group.

被引：0
|
作者：
Suzuki, Y.
Tokuda, Y.
Inoue, K.
Aogi, K.
Saito, M.
Yanagita, Y.
机构：
[1] Tokai Univ, Sch Med, Kanagawa 2591100, Japan
[2] Saitama Canc Ctr, Saitama, Japan
[3] Natl Hosp Org, Shikoku Canc Ctr, Shikoku, Ehime, Japan
[4] Juntendo Univ, Sch Med, Tokyo 113, Japan
[5] Gunma Canc Ctr, Gunma, Japan
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：280S / 280S
页数：1
相关论文
共 35 条
  • [1] Palonosetron (PALO) is effective in preventing chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 94 - 95
  • [2] A JAPANESE PHASE III OPEN-LABEL STUDY TO ASSESS SAFETY AND EFFICACY OF PALONOSETRON (PALO) 0.75 MG IV FOR PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN REPEATED CYCLES OF HIGHLY EMETOGENIC CHEMOTHERAPY. PALO JAPANESE COOPERATIVE STUDY GROUP
    Sakai, H.
    Aogi, K.
    Yoshizawa, H.
    Masuda, N.
    Katakami, N.
    Yanagita, Y.
    Inoue, K.
    Kuranami, M.
    Mizutani, M.
    Masuda, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 274 - 274
  • [3] PALONOSETRON (PALO) IS MORE EFFECTIVE THAN GRANISETRON (G) IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) ASSOCIATED WITH CISPLATIN (CDDP) - OR ANTHRACYCLINE PLUS CYCLOPHOSPHAMIDE (AC/EC) - BASED REGIMENS: RESULTS OF A PHASE III TRIAL - PALO JAPANESE COOPERATIVE STUDY GROUP
    Yoshizawa, H.
    Saito, M.
    Aogi, K.
    Sekine, I.
    Yanagita, Y.
    Sakai, H.
    Inoue, K.
    Kitagawa, C.
    Ogura, T.
    Mitsuhashi, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 275 - 275
  • [4] Pooled analysis of efficacy and safety of palonosetron 0.75 mg IV for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving cisplatin for lung cancer - Palonosetron Japanese Cooperative Study Group for lung cancer
    Ogura, Takashi
    Segawa, Yoshihiko
    Sekine, Ikuo
    Masuda, Noriyuki
    Katakami, Nobuyuki
    Sakai, Hiroshi
    Kubota, Kaoru
    Imamura, Fumio
    Atagi, Shinji
    Yoshizawa, Hirohisa
    Kitagawa, Chiyoe
    Takeda, Yuichiro
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S368 - S369
  • [5] Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
    Hesketh, Paul Joseph
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Alyasova, Anna
    Drobner, Igor
    Gralla, Richard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [7] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving anthracycline-cyclophosphamide (AC)-based chemotherapy
    Schnadig, Ian D.
    Modiano, Manuel R.
    Poma, Allen
    Arora, Sujata
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) for patients with breast cancer by CINV Study Group of Japan
    Saeki, T.
    Mukai, H.
    Fujimori, M.
    Ishikawa, T.
    Kai, Y.
    Tamaki, N.
    Noguchi, S.
    Doihara, H.
    Takeda, K.
    Ito, Y.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S91 - S91
  • [10] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving anthracycline-cyclophosphamide (AC) based chemotherapy.
    Powers, Daniel
    Schnadig, Ian D.
    Modiano, Manuel R.
    Arora, Sujata
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)
1234